Literature DB >> 21811050

Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate.

Elettra Merola1, Andrea Sbrozzi-Vanni, Francesco Panzuto, Giancarlo D'Ambra, Emilio Di Giulio, Emanuela Pilozzi, Gabriele Capurso, Edith Lahner, Cesare Bordi, Bruno Annibale, Gianfranco Delle Fave.   

Abstract

BACKGROUND: Type I gastric carcinoids (TIGCs) are neuroendocrine neoplasms arising from enterochromaffin-like cells in atrophic body gastritis. Data regarding their evolution in prospective series are scarce, thus treatment and follow-up are not codified. Our aim was to evaluate clinical outcome and recurrence in TIGCs managed by endoscopic approach.
METHODS: 33 patients (24 females; median age 65 years, range 23-81) were included and managed through endoscopic follow-up every 6-12 months, with lesion removal and multiple gastric biopsies. Baseline clinical and histological features were analyzed as risk factors by Cox regression.
RESULTS: At diagnosis, 7 tumors were intramucosal carcinoids and 26 were polyps (median diameter 5 mm, range 2-20), multiple in 17 patients. Associated severe atrophy was present in 21 cases (63.6%), while mild atrophy was found in 6 cases (18.2%). During a 46-month median follow-up, survival was 100% and no metastases occurred. One patient developed a less-differentiated carcinoid that was radically treated by surgery. 21 patients (63.6%) had recurrence after a median of 8 months, 14 of these (66.6%) had a second recurrence after a median of 8 months following the previous carcinoid removal. Median recurrence-free survival was 24 months. Neither clinical nor biochemical recurrence-predicting factors were found.
CONCLUSIONS: Although about 60% of TIGCs had recurrence after endoscopic resection, endoscopic management may be considered safe and effective.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21811050     DOI: 10.1159/000329043

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  37 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 2.  Endoscopic diagnosis and management of type I neuroendocrine tumors.

Authors:  Yuichi Sato
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

3.  Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study.

Authors:  Davide Campana; Davide Ravizza; Piero Ferolla; Antongiulio Faggiano; Franco Grimaldi; Manuela Albertelli; Debora Berretti; Danilo Castellani; Giulia Cacciari; Nicola Fazio; Annamaria Colao; Diego Ferone; Paola Tomassetti
Journal:  Endocrine       Date:  2015-03-27       Impact factor: 3.633

4.  Management of gastric carcinoids (neuroendocrine neoplasms).

Authors:  Mark Kidd; Bjorn I Gustafsson
Journal:  Curr Gastroenterol Rep       Date:  2012-12

5.  Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Authors:  Sylvain Manfredi; Thomas Walter; Eric Baudin; Romain Coriat; Philippe Ruszniewski; Thierry Lecomte; Anne-Pascale Laurenty; Bernard Goichot; Vincent Rohmer; Guillaume Roquin; Oana-Zvetlana Cojocarasu; Catherine Lombard-Bohas; Côme Lepage; Jeff Morcet; Guillaume Cadiot
Journal:  Endocrine       Date:  2017-06-29       Impact factor: 3.633

Review 6.  Laparoscopic resection of gastrointestinal neuroendocrine tumors with special contribution of radionuclide imaging.

Authors:  Andreas Shamiyeh; Michael Gabriel
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

7.  Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Authors:  Malcolm Boyce; Andrew R Moore; Liv Sagatun; Bryony N Parsons; Andrea Varro; Fiona Campbell; Reidar Fossmark; Helge L Waldum; D Mark Pritchard
Journal:  Br J Clin Pharmacol       Date:  2016-11-21       Impact factor: 4.335

Review 8.  Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms.

Authors:  Huangying Tan
Journal:  Transl Gastroenterol Hepatol       Date:  2016-11-29

Review 9.  How should incidental NEN of the pancreas and gastrointestinal tract be followed?

Authors:  Riccardo Ariotti; Stefano Partelli; Francesca Muffatti; Valentina Andreasi; Francesca Della Sala; Massimo Falconi
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

10.  Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.

Authors:  Quan-Lin Li; Yi-Qun Zhang; Wei-Feng Chen; Mei-Dong Xu; Yun-Shi Zhong; Li-Li Ma; Wen-Zheng Qin; Jian-Wei Hu; Ming-Yan Cai; Li-Qing Yao; Ping-Hong Zhou
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.